Targeting MET in cancer therapy

MET encodes a receptor tyrosine kinase c-MET for hepatocyte growth factor (HGF). The specific combination of c-MET and HGF activates downstream signaling pathways to trigger cell migration, proliferation, and angiogenesis. MET exon 14 alterations and MET gene amplification play a critical role in th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hong-Nan Mo, Peng Liu
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2017
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/de222e61f8fd42a8a74c780b8dd370cb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de222e61f8fd42a8a74c780b8dd370cb
record_format	dspace
spelling	oai:doaj.org-article:de222e61f8fd42a8a74c780b8dd370cb2021-12-02T10:50:32ZTargeting MET in cancer therapy2095-882X10.1016/j.cdtm.2017.06.002https://doaj.org/article/de222e61f8fd42a8a74c780b8dd370cb2017-09-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X16301633https://doaj.org/toc/2095-882XMET encodes a receptor tyrosine kinase c-MET for hepatocyte growth factor (HGF). The specific combination of c-MET and HGF activates downstream signaling pathways to trigger cell migration, proliferation, and angiogenesis. MET exon 14 alterations and MET gene amplification play a critical role in the origin of cancer. Several monoclonal antibodies and small-molecule inhibitors of c-MET have been evaluated in clinical trials. In patients with advanced non-small cell lung cancer, cabozantinib and crizotinib showed clear efficacy with a generally tolerable adverse events profile. In gastrointestinal cancers, most phase III trials of MET inhibitors showed negative results. In hepatocellular carcinoma, based on the encouraging results of some phase II studies, a series of phase III trials are currently recruiting patients to access the efficacy and safety of MET inhibitors. Keywords: Proto-oncogene protein c-MET, Antineoplastic agents, Protein kinase inhibitors, Molecular targeted therapyHong-Nan MoPeng LiuKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 3, Iss 3, Pp 148-153 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Hong-Nan Mo Peng Liu Targeting MET in cancer therapy
description	MET encodes a receptor tyrosine kinase c-MET for hepatocyte growth factor (HGF). The specific combination of c-MET and HGF activates downstream signaling pathways to trigger cell migration, proliferation, and angiogenesis. MET exon 14 alterations and MET gene amplification play a critical role in the origin of cancer. Several monoclonal antibodies and small-molecule inhibitors of c-MET have been evaluated in clinical trials. In patients with advanced non-small cell lung cancer, cabozantinib and crizotinib showed clear efficacy with a generally tolerable adverse events profile. In gastrointestinal cancers, most phase III trials of MET inhibitors showed negative results. In hepatocellular carcinoma, based on the encouraging results of some phase II studies, a series of phase III trials are currently recruiting patients to access the efficacy and safety of MET inhibitors. Keywords: Proto-oncogene protein c-MET, Antineoplastic agents, Protein kinase inhibitors, Molecular targeted therapy
format	article
author	Hong-Nan Mo Peng Liu
author_facet	Hong-Nan Mo Peng Liu
author_sort	Hong-Nan Mo
title	Targeting MET in cancer therapy
title_short	Targeting MET in cancer therapy
title_full	Targeting MET in cancer therapy
title_fullStr	Targeting MET in cancer therapy
title_full_unstemmed	Targeting MET in cancer therapy
title_sort	targeting met in cancer therapy
publisher	KeAi Communications Co., Ltd.
publishDate	2017
url	https://doaj.org/article/de222e61f8fd42a8a74c780b8dd370cb
work_keys_str_mv	AT hongnanmo targetingmetincancertherapy AT pengliu targetingmetincancertherapy
_version_	1718396620378210304

Targeting MET in cancer therapy

Ejemplares similares